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Background: With the emerging role of pharmacists in implementing smoking cessation services and the recent
evidence about smoking cessation pharmacotherapies, a needs analysis to assess baseline knowledge about current
smoking cessation practice is needed; hence, training and development in this area can target possible ‘gaps’.
Objective: This study aimed at exploring pharmacy students’ knowledge about and attitudes toward smoking
cessation, as compared to practicing community pharmacists and smoking cessation educators. The overall
objective was to uncover underlying ‘gaps’ in pharmacy-based smoking cessation practice, particularly clinical gaps.
Setting: Final-year pharmacy students at the University of Sydney, practicing community pharmacists and smoking
cessation educators in Australia.
Method: As no previous standard pharmacist-focused smoking cessation knowledge questionnaires exist, a review
of the literature informed the development of such a questionnaire. The questionnaire was administered to a
cohort of fourth-year pharmacy students at the University of Sydney, practicing pharmacists and smoking cessation
educators. Data analysis was performed using Predictive Analytics SoftWare (PASW® Statistics 18). Mean total scores,
independent t-tests, analysis of variances and exploratory factor analysis were performed.
Main outcome measure: To determine areas of major clinical deficits about current evidence related to smoking
cessation interventions at the pharmacy level.
Results: Responses from 250 students, 51 pharmacists and 20 educators were obtained. Smoking educators scored
significantly higher than pharmacists and students (P < .05), while score differences in the latter two groups were
not statistically significant (P > .05). All groups scored high on ‘general’ knowledge questions as compared to
specialised pharmacologic and pharmacotherapeutic questions. All respondents demonstrated positive attitudes
toward the implications of smoking cessation. Factor analysis of the 24-item knowledge section extracted 12 items
loading on 5 factors accounting for 53% of the total variance.
Conclusions: The results provide a valid indication of ‘gaps’ in the practice of up-to-date smoking cessation
services among Australian pharmacy professionals, particularly in clinical expertise areas involving assessment of
nicotine dependence and indications, dosages, adverse effects, contraindications, drug interactions and
combinations of available pharmacotherapies. These gaps should be addressed, and the results should inform the
design, implementation and evaluation of a pharmacy-based educational training program targeting current clinical
issues in smoking cessation.
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 This study represents the first Australian study
assessing knowledge about and attitudes toward
smoking cessation among pharmacy students and
community pharmacy practitioners.
 It revealed significant clinical/pharmacotherapeutic
gaps in the practice of current evidence-based
smoking cessation interventions at the pharmacy level.
 It developed and validated a questionnaire to
measure and assess smoking cessation-related
knowledge and attitudes.
 It provides guidance on key areas for future smoking
cessation education/training for pharmacy
professionals.
Introduction
The tobacco epidemic represents one of the biggest pub-
lic health threats affecting billions of lives (Shafey et al.,
2003). Smoking, as a result, remains to be a major cause
of preventable mortality and morbidity in the developed
world (Chandler and Rennard 2010).
With nicotine dependence being classified as a ‘dis-
ease’ in the World Health Organization International
Classification of Diseases (ICD-10-CM Diagnosis Codes
2013), addressing individual patient needs and providing
adequate treatment requires a thorough understanding
of the pharmacology of addiction, specialised therapeutic
knowledge and psychosocial intervention skills. Whilst
many smokers are able to quit ‘cold turkey’, therapeutic
services need to be tailored to meet the demands of re-
calcitrant smokers who cannot quit unassisted, those who
have had previous unsuccessful quit attempts and highly
dependent smokers with a greater prospect of relapse
(Chapman and MacKenzie 2013). This necessitates that
healthcare professionals be equipped with evidence-based
knowledge to facilitate smoking cessation interventions.
Smoking cessation research is dynamic, and new re-
vised guidelines suggest different approaches to those
used conventionally (Zwar et al., 2012; National Institute
for Health and Clinical Excellence 2008). Current emer-
ging recommendations debunk previous myths regarding
the use of smoking cessation aids. For instance, it is now
clear that nicotine replacement therapy (NRT) can be
used while still smoking, with a view to cutting down as
a prelude to quitting (Wennike et al., 2003; Rennard et
al., 2006). NRT can be used beyond the recommended
duration of 8 to12 weeks for as long as needed to help
patients quit (Medioni et al., 2005). In fact, NRT can be
continued after smoking lapses to promote recovery of
abstinence (Ferguson et al., 2012). It is also evident that
higher doses of NRT are more effective than lower doses,
particularly in highly dependent smokers (Stead et al.,
2012). Furthermore, the combination of more than oneform of NRT is significantly effective (Stead et al., 2012).
Indeed, NRT exhibits a wide safety profile and can be
administered during pregnancy after failure of non-
pharmacological interventions, in patients with cardio-
vascular diseases and in smokers aged 12 years and over
(Schroder et al., 2002; Coleman et al., 2011; Thomas
2012; Hanson et al., 2003); though many healthcare pro-
fessionals would be, based on conventional wisdom, un-
clear or hesitant to initiate this. Hence again, it is crucial
for healthcare practitioners to keep abreast in order to
successfully assist smokers in quitting.
Pharmacists, among other primary healthcare profes-
sionals, can play a fundamental role in smoking cessation.
They represent a highly accessible trained workforce with
a wide range of therapeutic expertise. They characterise
highly trusted practitioners with whom patients often con-
sult about health and medication-related issues (Pharmacy
Guild of Australia 2010). Moreover, in the last 2 decades,
community pharmacies have broadened their scope of ser-
vice to include, besides conventional medicine supply, a
variety of specialised services, such as health screening
and disease management (Schulz et al., 2001; Monte et al.,
2009). Pharmacists are well-positioned to provide smoking
cessation services within pharmacies, where smoking ces-
sation products are stocked and retailed. They can ap-
proach a wide spectrum of patients in need of support,
motivation and enhanced awareness about nicotine de-
pendence and avenues of treatment (Li 2010). Addition-
ally, systematic reviews, assessing the effectiveness of
pharmacist-delivered smoking cessation interventions, in-
dicated that trained community pharmacists, providing
counselling and ongoing support, may have a positive ef-
fect on abstinence rates (Roughead et al., 2003; Sinclair et
al., 2004; Dent et al., 2007). The counselling delivered by
pharmacists ranged in nature from simple advice about
the importance of smoking cessation, identifying barriers
to quitting and providing motivation to more intensive be-
havioural approaches such as providing support based on
the ‘stage-of-change model’ (Sinclair et al., 2004). Prelim-
inary studies also suggest that pharmacy-based smoking
cessation services are cost-effective (Sinclair et al. 1999;
Bauld et al., 2011).
In Australia, in 2011–12, it was estimated that nearly
20.4% of the adult male and 16.3% of the adult female
population were smokers (Australian Bureau of Statistics
2013). These rates are far lower than a quarter of a cen-
tury ago, and quit attempts have doubled since then
(Germain et al., 2012). In an attempt to provide disin-
centives to purchase tobacco products, new political and
social protocols have recently been instituted country-
wide. These included the implementation of the “plain”
(no brand images/advertisement) packaging legislation
and the raised taxes on cigarettes (Cancer Council
Victoria 2012). In Australia, over-the-counter NRT and
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(21 mg/24 hours and 15 mg/16 hours) and varenicline
can be accessed through subsidised pricing via the
Pharmaceutical Benefits Scheme, for a period of 12 weeks
for the patches and up to 24 weeks for varenicline. Des-
pite this infrastructure, little is known about the smok-
ing cessation services provided in this sector. Published
data suggest that sales of smoking cessation products
have increased, but only a minority of smoking cessation
product users report receiving any advice or support
(Bittoun 2007; Paul et al., 2003). Some studies have
shown that smokers consistently underutilise NRT, both
in terms of the number of pieces administered per day
and the duration of time that treatment is used
(Ferguson et al., 2011). For instance, despite Australia’s
active pharmacy practice researchers in the areas of
asthma, diabetes and Home Medicines Review (Australian
Government, Department of Health and Ageing 2009;
2011; The University of Sydney, Faculty of Pharmacy
2005), comprehensive pharmacy-delivered smoking ces-
sation programs have not been developed or evaluated
yet. This situation may also stem from lack of positive
attitudes toward pharmacist-delivered smoking cessation
services and the lack of pharmacists’ skills and confi-
dence in being able to provide these services in line with
the current therapeutic guidelines. In a previous simu-
lated patient study conducted in Sydney, authors con-
cluded that evidence-based smoking cessation advice in
pharmacies was fragile and may be compromised by
commercial concerns (Chiang and Chapman 2006). An-
other unclear issue is whether smoking cessation is han-
dled by pharmacy frontline staff or pharmacists.
Anecdotally, it is known that often Australian pharmacy
assistants may be in charge of the smoking cessation
products area. To add, whilst tobacco education is com-
mon in pharmacy schools in the United States (Corelli
et al., 2005), for instance, little is known about the depth
and scope of tobacco cessation content in Australian
pharmacy curricula. As a result, an identification of
needs, preferences and current awareness levels is cru-
cial, as for pharmacists to perform competent smoking
cessation interventions throughout their daily practice,
they need to attain and demonstrate knowledge, skills
and confidence in this field.
Given that early sources of knowledge that contribute
to one’s professional career are generally acquired at
professional courses, i.e., while undertaking a degree, it
was anticipated that mapping the knowledge and atti-
tudes of final-year pharmacy students would be an im-
portant marker of the “level of awareness” of pharmacy
professionals about smoking cessation. Pharmacy stu-
dents during their final year serve as a pertinent target
population because of their imminent entry into the pro-
fession, recency of knowledge acquisition, possiblepersonal smoking status or contact with peers who
smoke. It may also be hypothesised that experience with
providing smoking cessation services and advice should
enhance the skill base of professionals and that prac-
ticing professionals would have higher awareness and
more positive attitudes toward their role in smoking ces-
sation service provision.
Aim of the study
Therefore, the aim of this study was to assess the know-
ledge about and attitudes toward smoking cessation in
final-year pharmacy students and to compare the latter
with that of practicing pharmacists and specialised
smoking cessation educators. Accordingly, the overall
objective of this study was to uncover underlying ‘gaps’
in pharmacy-based smoking cessation practice, aiming at
investing the findings of this research in providing up-to
-date education to improve smoking cessation practice.
Methods
A cross-sectional questionnaire method was utilised.
Since there are no pre-existing standard tools in the lit-
erature that assess knowledge and attitudes regarding
smoking and smoking cessation, the first step was to de-
sign the questionnaire.
Questionnaire development
The “Smoking Cessation In Pharmacy (SCIP)” question-
naire was constructed by the principal author based on a
review of the literature (Centers for Disease Control and
Prevention 2005). The questionnaire comprised 4 sec-
tions as highlighted in Figure 1. The face and content
validity of the questionnaire were assessed by smoking
cessation experts, experienced practicing pharmacists
and academic pharmacists specialising in the field of
smoking cessation and respiratory health.
Sample selection
Three discrete groups were selected as the target popu-
lation–1) pharmacy students, 2) practicing pharmacists
and 3) smoking cessation educators. In Australia, the lat-
ter consists of a niche group of healthcare professionals,
usually specialised respiratory nurses, who have training
and experience in supporting patients to quit smoking.
Sample size
For group 1, a full cohort of pharmacy students, enrolled
at one of the largest pharmacy training provider univer-
sities in Australia, was selected. There was no existing
research on which to base a sample size calculation for
groups 2 and 3. We estimated that the knowledge score
of pharmacists may be at least 20% higher than that of
pharmacy students and that the knowledge score of
smoking cessation educators may be at least 40% higher
SECTION 1
DEMOGRAPHICS
It included 12 items, which were statements 
with YES/NO responses and SHORT 
ANSWER questions covering basic
demographic information and general data
about the participants’ smoking training
history and work experience.
SECTION 2a
KNOWLEDGE
It included 24 items (part 1), which were 
statements with TRUE/FALSE responses and
8 MULTIPLE CHOICE QUESTIONS (part 2)
pertaining to brief clinical cases and 
pharmacotherapeutic questions. This section
covered basic epidemiologic, pharmacologic
and therapeutic aspects of smoking/smoking
SECTION 3b
ATTITUDES
It included 18 items, which were statements 
with YES/NO responses that assessed the
respondents’ attitudes toward smoking,
smoking cessation practices and the
corresponding role of healthcare
professionals.
It included 16 items, which were statements
with YES/NO responses and SHORT 
ANSWER questions about the respondents’




Figure 1 The SCIP questionnaire. aSection 2 had a total possible score of 32 points (24 points from part 1 and 8 points for the correct answer
choice for part 2). bSection 3 had a total score of 18 points (allocated for choosing “yes” or “no” for appropriate attitudes).
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90% and a 2-sided significance level of 5%, a statistical
power calculation indicated that the study would require
50 pharmacists and 13 smoking cessation educators. The
study was approved by the Human Research Ethics Com-
mittee at the University of Sydney, protocol number 13046.
Recruitment strategies
Group 1- Final year pharmacy students at the University of
Sydney, one of the largest pharmacy provider uni-
versities in Australia, were recruited. A sampling frame
of all fourth-year pharmacy students enrolled in the
“Pharmacotherapeutics in Practice” course during semes-
ter 2, 2010, at the University of Sydney, was used. Tutors
in this course allocated 15 minutes for consenting stu-
dents to read project information and to complete and
hand in the questionnaires within a scheduled tutorial.
Group 2- It was anticipated that pharmacists could be
approached via the Pharmaceutical Society of Australia,
a national professional pharmacy organisation that rep-
resents Australian pharmacists working in varioussectors. Accordingly, all pharmacists who attended Con-
tinuing Education lectures run by the Pharmaceutical Soci-
ety of Australia in Sydney during November 2011 were
invited to participate. Measures were taken to ensure that
none of these lecture topics included smoking cessation-
related issues. Questionnaires were handed out prior to the
lecture, and consenting pharmacists were requested to
hand in the completed questionnaire forms after the com-
pletion of the activity.
Group 3- Smoking cessation educators were approached
via the Brain and Mind Research Institute Smoking Unit
(University of Sydney), which represents a leading Austra-
lian body in providing smoking cessation training and
conducting smoking cessation-related studies and clinical
trials. In November 2011, the questionnaire was emailed to
all smoking cessation educators whose names were on the
mailing list of the Brain and Mind Research Institute–Uni-
versity of Sydney Smoking Unit network. The inclusion cri-
teria were that participants in this group should have
previously completed at least 1 smoking cessation training
certificate and were running or working in respiratory/
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ministration. Participants were asked to return the ques-
tionnaires upon completion. Questionnaire collection was
completed by January 2012.
In all of the 3 groups, the questionnaire was administered
along with a participant information statement, which
highlighted the objectives of the research and assured partic-
ipants that their contribution was completely voluntary and
strictly confidential. The return of the completed question-
naires was sufficient evidence of consent to participate. No
reimbursement for participation in the study was offered.
Statistical analyses
Data from completed questionnaire was entered into the
Predictive Analytics SoftWare package (PASWW Statis-
tics 18) for analysis. Data from the demographic and
smoking history sections (SCIP sections 1 and 4) was
analysed using descriptive statistics. For Sections 2 and
3, mean total knowledge and attitude scores were calcu-
lated. Analysis of variance (ANOVA) and independent
sample t-tests were utilised to compare results between
and within groups. To explore the psychometric proper-
ties of the SCIP questionnaire, an exploratory factor ana-
lysis was performed for the 24 True/False (T/F)
knowledge items (SCIP section 2, part 1). Only this sec-
tion was included in the factor analysis, as this technique
is meaningful only when items are scored the same way.
The factor structures were analysed using a principal
components analysis and varimax rotation with Kaiser
normalization. The Kaiser Criterion (eigenvalues >1),
number of steps in the scree plot and the proportion of






















Missing data 0for the number of factors to be extracted. Items that had
poor factor loadings (<0.30) or that cross-loaded on 2 or
more factors were removed from the analysis (Pett et al.,
2003). The reliability of the remaining items was esti-
mated using Cronbach’s alpha coefficient, which mea-
sures the homogeneity of items within a scale (Carmines
and Zeller 1979).
Results
A total of 250 students (89.9% response rate), 51 pharma-
cists (72.9% response rate) and 20 smoking cessation educa-
tors (22.2% response rate) completed the questionnaire.
Overall, 90.3% of all the participants submitted completed
questionnaires, particularly providing answers to all the
questions in the knowledge and attitude sections.
Table 1 highlights the general demographic informa-
tion of respondents. Table 2 presents the mean total
knowledge and attitude scores for the 3 participant
groups. The mean knowledge score was not significantly
different between pharmacists and final-year pharmacy
students. However, both groups had significantly lower
knowledge scores than smoking cessation educators (P
< .05). Participants in all 3 groups had positive attitudes
toward smoking cessation and its implications.
The 32 knowledge questions in Section 2 of the question-
naire were then categorised into separate themes, for which
total scores were also calculated and compared among the
groups, as shown in Table 3. It was interesting to note that
when asked about the adverse effects of smoking or the
constituents of a cigarette, the scores were much higher
in all groups than when participants were asked about spe-

















Table 2 Total knowledge and attitude scores of respondents
Respondents Pharmacy students (A) Pharmacists (B) Smoking educators (C) ANOVA post hoc significance
Mean total knowledge score (%) ± SD
63.4% ± 9.8 65.2% ± 9.9 77.8% ± 6.3 A < B < C: P < .001
Range: Range: Range: A vs B: P > .05
34.3–87.5% 37.5–84.4% 65.6–90.6% A vs C: P < .05
B vsC: P < .05
Mean score–General knowledge section
(SCIP section 2, part 1–24 T/F)
71.4% ± 10.5 72.3% ± 10.5 85% ± 6.5
A < B < C: P < .001
A vs B: P > .05
A vs C: P < .05
B vs C: P < .05
Mean Score–Clinical/therapeutic section
(SCIP section 2, part 2–8 MCQs)
39.4% ± 18.0 43.9% ± 17.4 56.3% ±15.4
A < B < C: P < .001
A vs B: P > .05
A vs C: P < .05
B vs C: P < .05
Mean total attitude score (%) ± SD
88.8% ± 10.7 88.7% ± 8.17 92.5% ± 5.8 A < B < C: P = .279
Range: Range: Range: A vs B: P > .05
33.3–100% 66.7–100% 83.3–100% A vs C: P > .05
B vs C: P > .05
Significant P values are italicised.
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clinical/pharmacotherapeutic knowledge section (SCIP sec-
tion 2, part 2) were compared in Table 4. Both tables indi-
cate that ‘general’ knowledge was higher in all 3 groups as
compared with more specific professional knowledge. SCIP
section 2 part 1 comprised the ‘general knowledge’ section
that included a variety of questions related to smoking and
smoking cessation, such as the prevalence of smoking in
Australia, the adverse effects of smoking, nicotine depend-
ence and general pharmacotherapeutic-related issues ac-
quired throughout daily practice. On the other hand, SCIP
section 2 part 2 consisted of more specialised pharmaco-
therapeutic questions and clinical case scenarios. It was an-
ticipated that practitioners, who have previously received
smoking cessation training or those with extensive know-
ledge and expertise in the field of smoking cessation, would
respond to this section better than others. Appendix 1 and
Appendix 2 present both parts of the SCIP questionnaire
knowledge section.
Figures 2 and 3 illustrate total knowledge and attitude
score variability with respect to participant demograph-
ics. Table 5 summarises the ANOVA results for the lat-
ter. It was interesting to note that the recipients of some
form of training in smoking cessation had significantly
higher knowledge and more positive attitudes as com-
pared with those without this training.
For the 24-item knowledge section, factor analysis
extracted 5 primary factors with eigenvalues greater than
unity, accounting for 53% of the total variance and a
Kaiser–Meyer–Olkin measure of sampling adequacy of
0.6. Twelve items from the questionnaire were removedbecause of poor factor loading or cross loading on 2 fac-
tors. Thus, a 12-item version of the knowledge section
was retained after factor analysis and is referred to as
the SCIPV2 (Smoking Cessation In Pharmacy question-
naire Version 2). The 12 remaining items covered preva-
lence, pharmacology, assessment of dependence and
pharmacotherapeutic issues. Table 6 summarises the fac-
tor loadings and variance contribution of the items
retained in the knowledge section of SCIPV2. A relia-
bility analysis of the 12 retained items returned a
Cronbach’s alpha coefficient of 0.4. The total knowledge
scores were then recalculated for the 12 retained items
and compared among groups (Table 7). The pattern was
similar to that found in the original SCIP questionnaire,
i.e., the mean total knowledge score for the 12-item ver-
sion was not significantly different between pharmacists
and pharmacy undergraduate students. However, both
groups had significantly lower knowledge scores than
smoking cessation educators (P < .05). Table 8 summa-
rises the various smoking cessation elements that need
to be addressed in future research.
Discussion
Currently, there is no published literature assessing
Australian community pharmacists’ awareness about and
attitudes toward smoking-related health issues or smoking
cessation (El Hajj et al., 2012; Saulle et al., 2013;
Vanderhoek et al., 2013; Moxham et al., 2012); nor are
there any valid instruments measuring these factors. Given
the new clinical guidelines for the use of various pharma-
cotherapies (Wennike et al., 2003), it is imperative that
Table 3 Total scores of knowledge questions (SCIP Section2) classified into specific smoking-related themes
Total knowledge score (%)
Knowledge section (32 items) categories Pharmacy students (A) Pharmacists (B) Smoking educators (C) ANOVA post hoc significance
Epidemiology (3Qs) 54% ± 24.5 54.3% ± 29 81.7% ± 22.9
A < B < C: P < .001
A vs B: P > .05
A vs C: P < .05
B vs C: P < .05
Adverse effects of smoking (3Qs) 91.7% ± 16 92% ± 14.3 90% ± 15.7
A < B < C: P = .873
A vs B: P > .05
A vs C: P > .05
B vs C: P > .05
Forms of tobacco smoking (2Qs) 86% ± 26.9 85.5% ± 27 100%
A < B < C: P = .068
A vs B: P > .05
A vs C: P < .05
B vs C: P < .05
Cigarette constituents (2Qs) 91% ± 20.3 85.5% ± 23 87.5% ± 22.2
A < B < C: P = .180
A vs B: P > .05
A vs C: P > .05
B vs C: P > .05
Pharmacology of dependence (4Qs) 75.3% ± 22.6 80.5% ± 18.3 87.5% ± 17.2
A < B < C: P = .025
A vs B: P > .05
A vs C: P < .05
B vs C: P > .05
Assessment of Dependence (3Qs) 43% ± 27.6 43% ± 26.1 56.7% ± 21.9
A < B < C:P = .092
A vs B: P > .05
A vs C: P < .05
B vs C: P < .05
Pharmacotherapy (15Qs) 53.8% ± 14.1 57% ± 15.9 72% ± 10.9
A < B < C: P < .001
A vs B: P > .05
A vs C: P < .05
B vs C: P < .05
Significant P values are italicised.
Table 4 Proportion of correct answers for clinical/pharmacotherapeutic knowledge items (SCIP section 2, part 2)
Proportion of correct answers (%)
Overview of SCIP knowledge section 2 part 2 questions (8 MCQs) Pharmacy students Pharmacists Smoking educators
Quitting during pregnancy 64.8% 80.4% 100%
Smoking cessation in COPD with a history of major depression 61.2% 66.7% 80%
Contraindication of smoking cessation aids 20.8% 25.5% 15%
Age-related benefits of quitting (Fletcher-Peto graph) 56.4% 58.8% 70%
Tobacco-drug interactions 43.2% 39.2% 70%
Dosage of NRT (Possible reason for failure) 48.4% 60.8% 95%
Side effects of smoking cessation aids 5.2% 11.8% 20%
Smoking cessation in cardiovascular conditions 14.8% 7.8% 20%
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ticing pharmacists. This study has identified clear ‘gaps’ in
knowledge levels among Australian pharmacy profes-
sionals, particularly in clinical expertise areas involving as-
sessment of nicotine dependence and indications, dosages,
adverse effects, contraindications, drug interactions and
combinations of available pharmacotherapies (Beard et al.,
2012). Further, a smoking cessation questionnaire was de-
veloped and psychometrically evaluated with satisfactory
results. This instrument can be used in other studies and
as a basis for the evaluation of educational interventions
that focus on smoking cessation.
It was expected that smoking cessation educators, who
work with smokers on a daily basis, would achieve the
highest knowledge and attitude scores, and the obtained
results confirmed this assumption. Practicing commu-
nity pharmacists, who also encounter patients who
smoke or those requesting assistance with smoking ces-
sation, were expected to exhibit more positive attitudesFigure 3 Impact of various respondent-related criteria on total attitudand superior knowledge levels as compared to pharmacy
students. However, the results indicated no statistically
significant difference between the 2 groups. It should be
noted, though, that 51% of the pharmacists who com-
pleted the questionnaire were in the 20–29 age group.
This indicates that nearly half of the respondents in
group 2 were fresh pharmacy graduates with minimal
practical experience. This may have contributed to the
absence of statistical difference in total scores between
pharmacists and pharmacy students. Results indicated
that recipients of some form of training demonstrated
better knowledge (Zhang et al., 2012). Non-smokers
were also expected to score higher than smokers (Yang
et al., 2010); nevertheless, results revealed that, although
non-smokers exhibit more positive attitudes, both
groups share similar levels of knowledge. Gender was an
unexpected contributor to the variance in knowledge,
with females exhibiting higher knowledge levels and
more positive attitudes than males.e score.
Table 5 ANOVA results for the factors predicting knowledge and attitude scores
Scores between groups F Significance (P-value)
Gender
Total knowledge 3.151 .044
Total attitude 3.738 .025
Age
Total knowledge 3.036 .018
Total attitude .394 .813
Smoking status
Total knowledge 10.435 .000
Total attitude 15.484 .000
Smoking training history within university settings
Total knowledge 1.277 .280
Total attitude 0.773 .462
Smoking training history outside university settings
Total knowledge 2.928 .055
Total attitude 3.918 .021
Pharmacy-based workplace
Total knowledge 1.810 .165
Total attitude 0.461 .631
Significant P values are italicised.
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sation and the corresponding role of health profes-
sionals, interestingly, all 3 groups exhibited a certain
base level of ‘general’ knowledge about smoking and
smoking health-related issues. For instance, when asked
whether nicotine is the most addictive substance in a
cigarette or whether passive smoking is harmful to the
health, a high proportion of participants in all groups
responded correctly. This basic knowledge could be at-
tributed to the fact that smoking has become a common
public health issue and is a major focus of various public
health campaigns and mass media messages. On the
other hand, questions related to prevalence of smoking,Table 6 Principal component estimates of the varimax factor loa
Factors





Factor 2–Nicotine replacement therapy knowledge
Item 20
Item 21
Factor 3–Specialised smoking knowledge
Item 6
Item 24





Item 23pharmacology of nicotine dependence, methods of as-
sessment of nicotine dependence and pharmacotherapy
generated significantly lower scores. For items testing
knowledge of specific pharmacotherapeutic issues in-
cluding dosages, side effects, interactions and contrain-
dications of smoking cessation aids, smoking cessation
educators scored lower than pharmacists. For instance,
when asked which smoking cessation therapy is contra-
indicated in patients with severe hepatic impairment,
only 16% of smoking cessation educators answered cor-
rectly as compared with 27% of pharmacists and 23% of
students. However, when asked about the therapy that
could be associated with the development of suicidaldings for the 24 T/F knowledge items of the questionnaire


















Table 7 Total knowledge scores of the 12 items extracted by factor analysis
Respondents Pharmacy students (A) Pharmacists (B) Smoking educators (C) ANOVA post hoc significance
Mean score–general knowledge section
(Factor analysis 12 items)
62.9% ± 15.7 63.4% ± 17.5 82.9% ± 10.6 A < B < C: P < .001
Range: Range: Range: A vs B: P > .05
16.6–91.6% 25–91.7% 58.3–100% A vs C: P < .05
Mean TOTAL knowledge score (%) ± SD
(12 items + 8 MCQs)
53.5% ± 13.1 55.6% ± 14.1 72.3% ± 9.5 A < B < C: P < .001
Range: Range: Range: A vs B: P > .05
20–85% 20–85% 55–85% A vs C: P < .05
B vs C: P < .05
Significant P values are italicised.
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20% of educators answered correctly. This could be
explained by the fact that little is known about smoking
cessation aids beyond what is provided on the pack by
the manufacturers of NRT. Overall, the mean knowledge
scores for the various smoking-related themes matched
the total scores obtained by the 3 groups for both the
general and clinical-based knowledge sections; thus, this
trend indicates a reasonable extraction process and con-
struct validity.
The fact that pharmacists’ level of awareness is not
greater than that of students is a matter of concern. In a
previous simulated patient study conducted in Australia,
authors concluded that evidence-based smoking cessa-
tion advice in pharmacies was sub-optimal (Chiang and
Chapman 2006).
Factor analysis was used to establish construct validity
of the questionnaire. Although the reliability estimate
was low as characterised by the obtained Cronbach’s
alpha coefficient, this may be accounted for by the fact
that smoking and smoking cessation are viewed as gen-
eral social and public health topics, and therefore know-
ledge levels in such areas are expected to be diverse.
Total scores for the SCIPV2 (12 retained T/F items of
knowledge section), were significantly lower than the
scores for the 24-item original version, thus confirmingTable 8 Smoking cessation elements to be addressed in
future research
1 Overview of smoking–prevalence, adverse effects, benefits of quitting
2 Nicotine dependence–the ‘disease’
3 Pharmacokinetics of nicotine
4 Pathophysiology of dependence
5 Assessment of nicotine dependence–Fagreström test, expired CO levels,
urine/salive cotinine
6 Smoking cessation counselling–behavioural interventions, advice, support,
lifestyle modifications
7 Smoking cessation pharmacotherapy–products, dosage forms, dosages,
instructions for use, duration of therapy, adverse effects, precautions,
contraindications, interactions
8 Debunking myths–Safety of NRT, combinations of NRT, concomitant
smoking and NRT use, cut-down smoking regimensthat the factor analysis exercise allowed the deletion of
superfluous items, leaving a more streamlined version.
Score patterns obtained by the respective groups
(students = pharmacists < experts) were similar before
and after factor analysis, i.e., on both versions of the SCIP,
which indicates consistency.
A possible limitation of this study could be the small
sample size of smoking cessation educators (n = 20) as
compared with pharmacists (n = 51) and students (n = 250).
Furthermore, the methods of sample recruitment used for
groups 2 and 3 may have led to selection bias, as people
with strong beliefs or substantial knowledge, or those in-
terested in continuing education may be more willing to
respond to the questionnaire than others.
Future directions should explore the development, im-
plementation and evaluation of pharmacist-directed smok-
ing cessation educational programs that focus mainly on
‘deficit’ areas. Such programs should, therefore, incorpor-
ate diverse topics, including pharmacokinetics of nicotine
and pharmacology of dependence essential for dictating
pharmacotherapy (Benowitz 2008), different methods for
assessing dependence, such as carbon monoxide (CO)
monitoring and utilising the Fagerström test, psychosocial
behavioural interventions and a thorough exposure to
various pharmacotherapeutic aspects in light of current
clinical guidelines, as highlighted in Table 8. Tobacco ces-
sation education should all also be introduced into the
academic curricula of pharmacy and medical students.
Conclusions
Overall results of this study indicate the presence of
major clinical deficits about current evidence related to
smoking cessation interventions at the pharmacy level.
This study not only developed and validated a question-
naire to measure and assess smoking cessation-related
knowledge, but also provides guidance on key areas for
future smoking cessation education/training for phar-
macy professionals. Given the evidence for pharmacist-
delivered smoking cessation interventions and consumer
acceptance of the pharmacy as a venue for smoking ces-
sation services (Patwardhan and Chewning 2010), the
time is now pertinent to disseminate research on the
Saba et al. SpringerPlus 2013, 2:449 Page 11 of 13
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ing programs on pharmacy students’ and pharmacists’
awareness and confidence in the practice of smoking
cessation services.
Appendix 1
SCIP knowledge section (Section 2) part 1 with a True/
False response and the 12-item questions of SCIPV2
yielded by factor analysis in bold
1. In the last decade, smoking rates in Australia have
increased significantly. (F)
2. Besides the pulmonary adverse effects, smoking
causes cancer in various organs such as the bladder,
intestines and cervix. (T)
3. Deaths attributable to tobacco use in Australia
outnumber those caused by AIDS, legal drugs,
illegal drugs, road accidents, murder and suicide
combined. (T)
4. Passive smoking is not harmful to health. (F)
5. In smoking mothers, neonatal death may occur
secondary to tobacco smoke exposure. (T)
6. People with respiratory diseases, such as asthma,
tend to smoke more. (T)
7. Rolling your own cigarettes is safer than the
packaged industrial brands. (F)
8. The hubble- bubble which uses the water
mechanism is a safer way to smoke nicotine. (F)
9. Nicotine is the most addictive substance in a
cigarette. (T)
10. Nicotine is the most harmful substance in a
cigarette. (F)
11. In clinical settings, measuring CO levels is one of
the most reliable tests of nicotine dependence. (T)
12. Nicotine dependence is a chronic relapsing
disease. (T)
13. Nicotine dependence is mediated by dopamine
within the reward system of the brain. (T)
14. Nicotine withdrawal symptoms are associated with
increased noradrenergic outflow, secondary to
deactivation of the reward system. (T)
15. A heavy smoker is defined as someone who
smokes a total of 15 or more cigarettes/day. (F)
16. In Australia, smokers can be referred to specialised
smoking cessation clinics for treatment. (T)
17. Younger smokers find it easier to quit than
older smokers who have been smoking for a
longer time. (F)
18. The combination of behavioural and
pharmacological therapy has been shown to be
as effective as each alone. (F)
19. Nicotine replacement sublingual tablets and
patches are more effective than gums, lozenges
and inhalers. (F)20. One should never smoke if he/she is on
nicotine replacement therapy (NRT). (F)
21. Combining different forms of NRTs is
contraindicated. (F)
22. Varenicline is considered safe in smokers younger
than 18 years. (F)
23. Relapse is uncommon if patients comply with
their optimal smoking cessation plan. (F)
24. Some anti-depressants and anti-hypertensives can be
used as smoking cessation therapeutic options. (T)
Appendix 2
SCIP knowledge section (Section 2) part 2 with correct
answers in bold
1. M.N. is a 25 year old pregnant female who is trying to
quit smoking. Which statement is the most applicable?
A. Trying to quit smoking during pregnancy is
unsafe due to the development of withdrawal
symptoms in the baby.B. Check her smoking status first. If she is not
highly dependent, she may not need to quit.C. Behavioural therapy is not recommended
during pregnancy.D. NRT is safe during pregnancy and can be
used effectively.E. Champix is the most effective treatment to be
used during pregnancy.2. D.B. is a 50 year old female suffering from severe
hypertension and major depression, associated with
several unsuccessful suicide attempts. She has been
smoking 20 cigarettes/day for 25 years and was
recently diagnosed with COPD. Her current
medications include fluoxetine, diltiazem and
perindopril. Which agent would you recommend to





E. Combination NRT and Bupropion
3. Which of the following is contraindicated in




D. None of the above
E. All of the above
4. J.A. is a 60 year old heavy smoker. His
grandchildren are refusing to sit next to him
because “poppy stinks”. Which of the following
statements are correct?
A. Stopping smoking at the age of 60 will not
restore any of his lung function.
Saba et al. SpringerPlus 2013, 2:449 Page 12 of 13
http://www.springerplus.com/content/2/1/449B. If he had quit smoking at the age of 45, his
lung function would have improved and
become similar to that of a non-smoker.C. If he quits now, his lung function will
improve by up to 10% within 9 months.D. Quitting smoking now will not decrease his
risk of developing a heart attack.E. Quitting smoking now will not reduce his risk





D. None of the above
E. All of the above
6. E.Y. is a 35 year old male who smokes 25
cigarettes/day and is trying to quit smoking. He has
been counselled by his pharmacist to start Step 1 of
Nicorette® 15 mg patch as follows: For 8 weeks,
apply 1 patch every morning, and remove it before
going to bed. Eight weeks later, E.Y. claims that he
has completely followed the instructions yet was
unsuccessful; therefore he wants to change his
current treatment. What could be the most possible
reason behind E.Y.’s failure to quit?
A. He has no will power to quit.
B. He must have been smoking while he was onthe patch.
C. Step 1 of a 16 hour patch should have beenstarted rather than that of a 24 hour patch.
D. One 15 mg patch per day is probably toolow a dose in his case.
E. None of the above
7. The development of suicidal ideations is a common





D. None of the above
E. All of the above
8. A.K. is a 55 year old male who has been a chronic
smoker since 20 years of age. 12 hours ago, he had
a myocardial infarction. Being hospitalised, he was
unable to smoke, and he is starting to feel restless.
His doctor decided to start a smoking cessation
plan. Which therapy will be most appropriate to





E. None of the aboveAbbreviations
SCIP: Smoking cessation In pharmacy; NRT: Nicotine replacement therapy;
CO: Carbon monoxide; SCIPV2: Smoking cessation In pharmacy questionnaire
version 2.
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